Table 2.
Developmental outcomes of neonates with CGISC*
| Major gastrointestinal anomaly | No | Mortality | SNDO among infants who were assessed | Median GQ |
| Gastroschisis | 92 (22.3%) | 3/92 (3.3%) | 8/55 (14.5%) | 98.5 (IQR:92.5–103) n=60 |
| Malrotation | 48 (11.6%) | 3/48 (6.2%) | 4/33 (12.1%) | 96 (IQR:93–103) n=34 |
| Oesophageal atresia | 44 (10.6%) | 1/44 (2.3%) | 10/27 (37%) | 93 (IQR:85–100) n=27 |
| Hirschsprung disease | 44 (10.6%) | 1/44 (2.3%) | 6/32 (18.7%) | 98 (IQR:93–102) n=33 |
| Congenital diaphragmatic hernia | 42 (10.2%) | 1/42 (2.4%) | 5/34 (14.7%) | 94.5 (IQR:92–105) n=34 |
| Ano-rectal anomalies | 39 (9.4%) | 0/39 (0%) | 3/21 (14.3%) | 96 (IQR:90–101) n=22 |
| Gut perforations and stenoses | 19 (4.6%) | 1/19 (5.3%) | 1/12 (8.3%) | 101.5 (IQR:94.5–106) n=12 |
| Duodenal atresia | 19 (4.6%) | 0/19 (0%) | 1/13 (7.7%) | 99 (IQR:94–110) n=15 |
| Jejuno-Ileal atresia | 16 (3.9%) | 0/16 (0%) | 1/9 (11.1%) | 97.5 (IQR:95–102) n=10 |
| Exomphalos | 13 (3.1%) | 0/13 (0%) | 1/6 (16.7%) | 99 (IQR:89–100) n=7 |
| Meconium Ileus | 12 (2.9%) | 0/12 (0%) | 0/5 (0%) | 98 (IQR:96–99) n=5 |
| Multiple gut anomalies | 10 (2.4%) | 1/10 (10%) | 3/7 (42.8%) | 88 (IQR:84–100) n=7 |
| Short bowel syndrome | 5 (1.2%) | 2/5 (40%) | 0/1 (0%) | 95 n=1 |
| Large bowel atresia | 5 (1.2%) | 0/5 (0%) | 0/1 (0%) | 104 n=1 |
| Benign abdominal cysts and tumours | 4 (0.97%) | 0/4 (0%) | 0/1 (0%) | 103 n=1 |
| Biliary atresia | 1 (0.24%) | 0/1 (0%) | 0/1 (0%) | 92 n=1 |
*For all outcomes, infants who underwent at least one episode of surgery were included; infants who died prior to undergoing any surgery were excluded. The information on neurodevelopmental outcomes was available for 65% of survivors.
CGISC, congenital gastrointestinal surgical conditions; GQ, general quotient; SNDO, suboptimal neurodevelopmental outcomes.